QIPP Prescribing Comparators: Description and Specification

Size: px
Start display at page:

Download "QIPP Prescribing Comparators: Description and Specification"

Transcription

1 Prescribing s: Description and Specification This document details the descriptions and specifications for the prescribing comparators. They should be read in conjunction with the National Prescribing Centre Publication - Key s 2010/11 (July 2010). A set of 14 comparators have been developed to support the (Quality, Innovation, Productivity and Prevention) medicine use and procurement workstream. The comparators have been developed as a part of the workstream lead by Peter Rowe, National Workstream lead Medicine Use and Procurement Department of Health. They have been developed following discussion and feedback within the medicine steering and wider reference groups and SHA leads and industry partners. The comparators cover 11 of the 15 therapeutic areas covered in the National Prescribing Centre Publication Key s 2010/11 (July 2010). Please refer to this publication for details of the key therapeutic messages, options for local implementation and supporting evidence The aim of the comparators is to allow organisations and prescribers to review the appropriateness of current prescribing, revise prescribing where appropriate and monitor implementation. The comparators are not intended to be used as targets or performance tables but rather highlight variation and support local discussion and decisions regarding. values are available via NHSBSA Prescription Services Prescribing. NB: Blood glucose monitoring will be available soon via. Values are available via PCT charts and data tables (see below) A set of charts and data tables showing values for all PCT values are available on the NHSBSA website (insert link). Individual PCTs can be highlighted by selecting the PCT from the drop down menu on each chart. 1

2 Summary of Prescribing s: NPC Key comparator description Prescribing 1. Renin-angiotensin system Number of prescription items for angiotensin converting enzyme (ACE) 1. ACE inhibitor % items drugs inhibitors as a percentage of the total number of prescription items for all drugs affecting the renin-angiotensin system excluding aliskiren. 2. Statins Number of prescription items for simvastatin and pravastatin as a percentage 2. Low cost lipid modifying drugs of the total number of prescription items for all statins, including combination of simvastatin/ezetimibe, and ezetimibe 3. Newer hypoglycaemics Number of prescription items for metformin and sulphonylureas as a 3. Old versus new antidiabetic 4. Proton Pump Inhibitors (PPIs) 5. Non-steroidal antiinflammatory drugs (NSAIDs) 7. Long acting insulin analogues percentage of the total number of prescription items for all antidiabetic drugs. Number of prescription items for low cost PPI preparations (omeprazole, lansoprazole and pantoprazole) as a percentage of the total number of prescription items for all PPIs. Number of prescription items for ibuprofen and naproxen as a percentage of the total number of prescription items for all NSAIDs. Number of average daily quantities (ADQs) per Star-PU for all NSAIDs (BNF section ) Number of prescription items for long acting human analogue insulins detemir and glargine as a percentage of the total number of prescription items for all long acting and intermediate acting insulins excluding biphasic insulins. drugs 4. Low cost PPIs % items 5. NSAIDS: Ibuprofen & naproxen % items 6. NSAIDs: ADQ/STAR PU 7. Long/intermediate insulin analogues 8. Self-monitoring of blood glucose (SMBG) in type 2 diabetes Cost of SMBG strips per patient on QoF diabetes register. 8. Blood glucose monitoring cost/patient NB: Not yet available via 9. Clopidogrel Generic prescribing rate for clopidogrel 9. Clopidogrel generic prescribing 11. Antibacterial prescribing especially quinolones and cephalosporin Number of prescription items for antibacterial drugs (BNF 5.1) per Star-PU Number of prescription items for cephalosporins and quinolones as a percentage of the total number of prescription items for selected* antibacterial drugs (BNF 5.1) 12. Hypnotics Total number of average daily quantities (ADQs) for benzodiazepines (indicated for use as hypnotics) and Z drugs per Star-PU*. 15. Alendronate Generic prescribing rate for alendronic acid (sodium alendronate) Number of prescription items for alendronic acid (sodium alendronate) as a percentage of the total number of prescription items for all bisphosphonates and other drugs affecting bone metabolism (BNF 6.6.2) rate 10. Antibacterial items/star PU, 11. Cephalosporins & quinolones % items 12. Hypnotics ADQ/STAR PU 13. Alendronate generic prescribing rate 14. Alendronate as % of all bisphosphonates 2

3 1 1. Renin-angiotensin system drugs - page 3 Number of prescription items for angiotensin converting enzyme (ACE) inhibitors as a percentage of the total number of prescription items for all drugs affecting the renin-angiotensin system excluding aliskiren. ACE inhibitor % items Items for BNF section (ACE inhibitors) Angiotensin-Converting Enzyme Inhibitors Denominator Items for BNF sections (ACE inhibitors) and (angiotensin-ii receptor antagonists). Angiotensin-Converting Enzyme Inhibitors Angiotensin-II Receptor Antagonists Denominator excludes renin inhibitors (BNF section ) i.e. aliskiren. 3

4 2 2. Statins / Lipid modifying drugs - page 3 Number of prescription items for simvastatin and pravastatin as a percentage of the total number of prescription items for all statins, including combination of simvastatin/ezetimibe, and ezetimibe Low cost lipid modifying drugs Items for simvastatin and pravastatin (sub-set of BNF 2.12) Pravastatin Sodium Simvastatin X Y0 Denominator Items for all statins, including combination of simvastatin / ezetimibe, and ezetimibe (sub-set of BNF section 2.12). Atorvastatin Cerivastatin Ezetimibe Fluvastatin Sodium Lovastatin Pravastatin Sodium Rosuvastatin Calcium Simvastatin Simvastatin & Ezetimibe B C L M R X AA Y AC Generic prescribing rate for pravastatin and simvastatin is high. Cerivastatin and lovastatin nil prescribing due to products being withdrawn / unavailable in UK. 4

5 3 3. Newer hypoglycaemics - page 4 Number of prescription items for metformin and sulphonylureas as a percentage of the total number of prescription items for all antidiabetic drugs. Old versus new antidiabetic drugs Items for BNF section and BNF section Biguanides Sulphonylureas Denominator Items for BNF section (antidiabetic drugs) Antidiabetic Drugs

6 4 4. Proton Pump Inhibitors (PPIs) page 5 Number of prescription items for low cost PPI preparations (omeprazole, lansoprazole and pantoprazole) as a percentage of the total number of prescription items for all PPIs. Low cost PPIs % items Items for omeprazole, lansoprazole and pantoprazole (sub-set of BNF 1.3.5) * Lansoprazole Omeprazole Pantoprazole L P R0 Denominator Items for BNF section (proton pump inhibitors) ** Esomeprazole Lansoprazole Omeprazole Pantoprazole Rabeprazole Sodium E L P R T0 See comments below * No attempt made to exclude orodispersible preparations such as MUPs and FasTabs from numerator. Difficulties in defining low cost as current costs are now lower. ** Denominator excludes helicobacter pylori eradication. Currently no preparations available. Helicobacter Pylori Eradication Therapy A0 6

7 5 5. Non-steroidal anti-inflammatory drugs (NSAIDs) page 5 Number of prescription items for ibuprofen and naproxen as a percentage of the total number of prescription items for all NSAIDs. NSAIDS: Ibuprofen & naproxen % items Items for ibuprofen and naproxen (sub-set of BNF section ) Ibuprofen J0 Ibuprofen Lysine AD Naproxen P0 Naproxen Sodium Denominator Items for BNF section (non-steroidal ant-inflammatory drugs) Non-Steroidal Anti-Inflammatory Drugs

8 6 5. Non-steroidal anti-inflammatory drugs (NSAIDs) page 5 Number of average daily quantities (ADQs) per Star-PU for all NSAIDs (BNF section ) NSAIDs: ADQ/STAR PU Total ADQ usage for BNF section Non-Steroidal Anti-Inflammatory Drugs Denominator Number of Star-PUs for BNF section Cost based Oral NSAIDs SUB THERA STAR (09) PUs Oral NSAIDs (BNF ) age group Male Female Existing PPD volume comparator. 99.4% of items are covered by ADQ values. 8

9 7 7. Long acting insulin analogues page 7 Number of prescription items for long acting human analogue insulins detemir and glargine as a percentage of the total number of prescription items for all long acting and intermediate acting insulins excluding biphasic insulins. Long/intermediate insulin analogues Items for insulin detemir and insulin glargine (sub-set of BNF section ) Insulin Detemir Insulin Glargine X V0 Denominator Items for all long acting and intermediate acting insulins excluding* biphasic insulins (sub-set of BNF section ). Insulin Detemir X0 Insulin Glargine V0 Insulin Zinc Suspension G0 Insulin Zinc Suspension (Amorphous) L0 Insulin Zinc Suspension (Crystalline) N0 Isophane Insulin S0 Other Intermed&Long-Acting Insulin Preps Protamine Zinc Insulin U0 * Denominator excludes following: Biphasic Insulin Injection Biphasic Insulin Lispro Biphasic Isophane Insulin Biphasic Protamine Insulin C F D W0 9

10 8 8. Self-monitoring of blood glucose (SMBG) in type 2 diabetes mellitus page 7 Cost of SMBG strips per patient on QoF diabetes register. Blood glucose monitoring cost/patient. NB: Not yet available via * Cost (Net Ingredient Cost) for Epact BNF code D0 (selfmonitoring blood glucose strips). Glucose Blood Testing Reagents D0 Denominator Number of patients on QoF diabetes register. Values available from prevalence tables: Copy of QOF0910_Pracs_Prevalence.xls Copy of QOF0910_PCTs_Prevalence.xls Copy of QOF0910_SHAs_Prevalence.xls Unlike the BNF, it is possible in epact to identify and separate Glucose Blood Monitoring Reagents from other reagents, listed in BNF section 6.1.6, using BNF code D0 QoF tables updated in October for the financial year ending March. NB: QoF includes all patients with diabetes over age of 17. * currently does not have the functionality to import data from external sources. Therefore the comparator is not yet available via. 10

11 9 9. Clopidogrel page 8 Generic prescribing rate for clopidogrel Clopidogrel generic prescribing rate Items for clopidogrel written by approved name Clopidogrel C0AA Denominator Total items for all prescribing for clopidogrel Clopidogrel C0 11

12 Antibacterial prescribing especially quinolones and Cephalosporins page 9 Number of prescription items for antibacterial drugs (BNF 5.1) per Star-PU Antibacterial items/star PU Items for BNF section 5.1 Antibacterial Drugs 0501 Denominator Number of Star-PUs (for BNF section 5.1) Item based Antibacterial (5.1) Star (09) PU Antibacterial ( BNF 5.1) age group Male Female ADQ per Star-PU is an existing PPD volume comparator. includes all of BNF 5.1. Paragraphs excluded from comparator 10 (see below) only account for 0.6% of all items for BNF 5.1. Star (09) PU values based on all of 5.1 therefore should not exclude certain paragraphs / sub-paragraphs from numerator. 12

13 Antibacterial prescribing especially quinolones and cephalosporins page 9 Number of prescription items for cephalosporins and quinolones as a percentage of the total number of prescription items for selected* antibacterial drugs (BNF 5.1) Cephalosporins & quinolones % items Items for BNF sections (cephalosporins) and (quinolones) Cephalosporins Quinolones Denominator Items for BNF sections 5.1.1; ; 5.1.3; 5.1.5; 5.1.8; ; ; )* Cephalosporins Macrolides Metronidazole, Tinidazole & Ornidazole Penicillins Quinolones Sulphonamides And Trimethoprim Tetracyclines Urinary-Tract Infections Denominator attempts to exclude specialist antibiotics that do not provide a suitable alternative to quinolones and cephalosporins. Better supports potential efficiency/cost tools. Prescribing of injectables within cephalosporins ( ) neglible (0.12% items for qtr 1 and qtr /11) therefore no attempt to exclude from numerator. Likewise for quinolones. No prescribing for Cephalosporins and other Beta-Lactams ( ) therefore excluded from numerator (contains mainly injectable preparations). 13

14 12. Hypnotics page 9 12 Total number of average daily quantities (ADQs) for benzodiazepines (indicated for use as hypnotics) and Z drugs per Star-PU*. Hypnotics ADQ/STAR PU ADQ usage for benzodiazepines in BNF section and Z drugs (zolpidem, zopiclone and zaleplon) in BNF section Flunitrazepam Flurazepam Hydrochloride Loprazolam Mesilate Lormetazepam Nitrazepam Temazepam Triazolam Zaleplon Zolpidem Tartrate Zopiclone I L N P R T V W Y Z0 Denominator Number of Star-PUs** Cost based drugs acting on benzodiazepine receptors Star (09) PU* Drugs acting on Benzodiazepine receptors age group Male Female ** Star-PU values are based on all benzodiazepine and Z drugs acting on benzodiazepine receptors i.e. includes benzodiazepines indicated for use as anxiolytics (sub-set of BNF section 4.1.2) Star-PU values for proposed numerator are not available. 14

15 13 Alendronate page 11 Generic prescribing rate for alendronic acid (sodium alendronate) Alendronate generic prescribing rate Items for alendronic acid prescribed by approved name Alendronic Acid A0AA Denominator Total items for all prescribing for alendronic acid Alendronic Acid A0 15

16 14 Alendronate page 11 Number of prescription items for alendronic acid (sodium alendronate) as a percentage of the total number of prescription items for all bisphosphonates and other drugs affecting bone metabolism (BNF 6.6.2) Alendronate as % of all bisphosphonates All items for alendronic acid Alendronic Acid A0 Denominator All items for BNF section Bisphosphonates and Other Drugs

Wirral CCG Prescribing Incentive Scheme Summary

Wirral CCG Prescribing Incentive Scheme Summary Wirral CCG Prescribing Incentive Scheme 13-14 Summary Wirral wide scheme to run from July 2013 February 2014. Incentive monies available up to 1.50 per head of practice population (based on April 2013

More information

NATIONAL PRESCRIBING INDICATORS DRUG BASKETS

NATIONAL PRESCRIBING INDICATORS DRUG BASKETS NATIONAL PRESCRIBING INDICATORS 2014 2015 DRUG BASKETS INTRODUCTION The National Prescribing Indicators (NPIs) 2014 2015 were developed by the All Wales Prescribing Advisory Group (AWPAG), and underwent

More information

NATIONAL PRESCRIBING INDICATORS ANALYSIS OF PRESCRIBING DATA: DECEMBER April 2013

NATIONAL PRESCRIBING INDICATORS ANALYSIS OF PRESCRIBING DATA: DECEMBER April 2013 NATIONAL PRESCRIBING INDICATORS 2012 2013 ANALYSIS OF PRESCRIBING DATA: DECEMBER 2012 April 2013 This report has been prepared by the Welsh Analytical Prescribing Support Unit (WAPSU), part of the All

More information

National Prescribing Indicators Annual Primary Care Prescribing Report

National Prescribing Indicators Annual Primary Care Prescribing Report National Prescribing Indicators 214 215 Annual Primary Care Prescribing Report This report has been prepared by the Welsh Analytical Prescribing Support Unit (WAPSU), part of the All Wales Therapeutics

More information

NATIONAL PRESCRIBING INDICATORS ANALYSIS OF PRESCRIBING DATA TO DECEMBER 2014

NATIONAL PRESCRIBING INDICATORS ANALYSIS OF PRESCRIBING DATA TO DECEMBER 2014 NATIONAL PRESCRIBING INDICATORS 2014 2015 ANALYSIS OF PRESCRIBING DATA TO DECEMBER 2014 May 2015 This report has been prepared by the Welsh Analytical Prescribing Support Unit (WAPSU), part of the All

More information

PDP 406 CLINICAL TOXICOLOGY

PDP 406 CLINICAL TOXICOLOGY PDP 406 CLINICAL TOXICOLOGY Pharm.D Fourth Year NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) Mr.D.Raju.M.Pharm., Lecturer OPTIONS FOR LOCAL IMPLEMENTATION (1) NPC. KEY THERAPEUTIC TOPICS MEDICINES MANAGEMENT

More information

Therapeutic options for adult patients unable to take solid oral dosage forms (Adapted from UKMi Q&A for use in Northern Ireland) Sep 2015

Therapeutic options for adult patients unable to take solid oral dosage forms (Adapted from UKMi Q&A for use in Northern Ireland) Sep 2015 Therapeutic options for adult patients unable to take solid oral dosage forms (Adapted from UKMi Q&A 294.3 for use in Northern Ireland) Sep 2015 BNF 1.3.5 Proton pump inhibitors Lansoprazole orodispersible

More information

High use of maintenance therapy after triple therapy regimes in Ireland

High use of maintenance therapy after triple therapy regimes in Ireland High use of maintenance therapy after triple therapy regimes in Ireland K Bennett, H O Connor, M Barry, C O Morain, J Feely Department of Pharmacology & Therapeutics Department of Gastroenterology Trinity

More information

Outline. Definitions. ATC Anatomical Therapeutic Chemical classification

Outline. Definitions. ATC Anatomical Therapeutic Chemical classification The Anatomical Therapeutic Chemical Classification and the Defined Daily Dose: Classifying and Quantifying Drug Use Hanne Strøm Department of Pharmacoepidemiology ICPE, Chicago August 2011 : Preconference

More information

Guide to the Modernized Reference Drug Program

Guide to the Modernized Reference Drug Program Guide to the Modernized Reference Drug Program For prescribers and pharmacists Medical Beneficiary and Pharmaceutical Services Division June 1, 2016 Contents 1 Introduction 1 2 About this Guide 2 3 About

More information

MeReC Bulletin. MeReC Publications. Vol.22 No.03 January 2012

MeReC Bulletin. MeReC Publications. Vol.22 No.03 January 2012 MeReC Bulletin Vol.22 No.03 January 2012 MeReC Publications Implementing key therapeutic topics: 1 NSAIDs; antibiotics; and inhaled corticosteroids in asthma The QIPP agenda aims to ensure that value for

More information

GASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA

GASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA GASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA MANAGEMENT Dyspepsia refers to a spectrum of usually intermittent upper gastrointestinal symptoms, including epigastric pain and heartburn. For the majority

More information

Rpts. GENERAL General Schedule (Code GE) Program Prescriber type: Dental Medical Practitioners Nurse practitioners Optometrists Midwives

Rpts. GENERAL General Schedule (Code GE) Program Prescriber type: Dental Medical Practitioners Nurse practitioners Optometrists Midwives Esomeprazole 20mg Name, Restriction, Manner of esomeprazole 20 mg enteric tablet, 30 (8886Q) (029W) Gastric ulcer Peptic ulcer Treatment Phase: Initial treatment The therapy must be for initial treatment

More information

National Prescribing Indicators Analysis of Prescribing Data to September 2015

National Prescribing Indicators Analysis of Prescribing Data to September 2015 National Prescribing Indicators 2016 Analysis of Prescribing Data to tember National Prescribing Indicators 2016. Analysis of Prescribing Data to tember EXECUTIVE SUMMARY The All Wales Medicines Strategy

More information

PRESCRIBING INDICATORS UPDATED FEBRUARY 2010

PRESCRIBING INDICATORS UPDATED FEBRUARY 2010 PRESCRIBING INDICATORS 2010-11 UPDATED FEBRUARY 2010 This paper sets out the proposed national prescribing indicators for 2010/11 retaining efficiency and safety principles as a means to monitor Local

More information

Proton Pump Inhibitor De-prescribing Guidance

Proton Pump Inhibitor De-prescribing Guidance Amendment History Proton Pump Inhibitor De-prescribing Guidance VERSION DATE AMENDMENT HISTORY 1.0 2013 Previous version 2.0 September 2015 Comments Amendment to Flow chart and addition of Rationale page

More information

Lipid Lowering in patients with High Risk of Cardiovascular Disease (Primary Prevention)

Lipid Lowering in patients with High Risk of Cardiovascular Disease (Primary Prevention) Lipid Lowering in patients with High Risk of Cardiovascular Disease (Primary Prevention) Policy Statement: October 2010 This policy defines the decision made by NHS Wirral following an evidence review

More information

Omeprazole 10mg. Name, Restriction, Manner of administration and form OMEPRAZOLE omeprazole 10 mg enteric tablet, 30 (8332M) Max. Qty.

Omeprazole 10mg. Name, Restriction, Manner of administration and form OMEPRAZOLE omeprazole 10 mg enteric tablet, 30 (8332M) Max. Qty. Omeprazole 10mg Name, Restriction, Manner of administration and form omeprazole 10 mg enteric tablet, 30 (8332M) Gastro-oesophageal reflux disease Name, Restriction, Manner of administration and form omeprazole

More information

Rpts. GENERAL General Schedule (Code GE)

Rpts. GENERAL General Schedule (Code GE) Pantoprazole 20mg Name, Restriction, Manner of administration and form Pantoprazole 20mg enteric tablet, 30 (8399C) Gastro-oesophageal reflux disease Name, Restriction, Manner of administration and form

More information

New Measure Recommended for Endorsement by PQA

New Measure Recommended for Endorsement by PQA New Measure Recommended for Endorsement by PQA Measure: Statin Use in Persons with Diabetes Description: The percentage of patients ages 40 75 years who were dispensed a medication for diabetes that receive

More information

Calgary Long Term Care Formulary

Calgary Long Term Care Formulary Page 1 of 14 Calgary Long Term Care Formulary Pharmacy & Therapeutics Highlights https://www.albertahealthservices.ca/info/page4071.aspx Page 2 of 14 Contents... 3 Formulary Changes (Additions, Changes,

More information

MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)

MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Routine endoscopic investigation of patients of any age, presenting with dyspepsia

More information

Found in practice. Joint Formulary. Joint Formulary. Embedded into practice. Embedded into practice. As above. As above.

Found in practice. Joint Formulary. Joint Formulary. Embedded into practice. Embedded into practice. As above. As above. IPSWICH HOSPITAL ADULT THERAPEUTIC SUBSTITUTION REGISTER FOR PHARMACISTS What s New? New Substitutions Added exclusion criteria of Recommended by psychiatry to escitalopram switch Enoxaparin 40mg to 20mg

More information

Proton Pump Inhibitors Drug Class Prior Authorization Protocol

Proton Pump Inhibitors Drug Class Prior Authorization Protocol Proton Pump Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review

More information

Proton Pump Inhibitors. Description

Proton Pump Inhibitors. Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.01 Subject: Proton Pump Inhibitors Page: 1 of 6 Last Review Date: June 24, 2015 Proton Pump Inhibitors

More information

NICE update. Paul Chrisp, Programme Director, Medicines and Prescribing Centre

NICE update. Paul Chrisp, Programme Director, Medicines and Prescribing Centre NICE update Paul Chrisp, Programme Director, Medicines and Prescribing Centre Outline NICE offers a comprehensive suite of guidance, advice and support for delivering quality, safety and efficiency in

More information

Management of Dyspepsia

Management of Dyspepsia MPharm Programme Management of Dyspepsia Slide 1 of 28 Learning Objectives Understand the principles and wider implications underpinning evidence based therapeutics in the key clinical specialities Objectively

More information

Drug Class Monograph

Drug Class Monograph Drug Class Monograph Class: Proton Pump Inhibitors Drugs: Aciphex Sprinkle (rabeprazole), Dexilant (dexlansoprazole), Lansoprazole, Nexium (esomeprazole capsule, esomeprazole granules), Omeprazole, Pantoprazole,

More information

The Infection Control Doctor and Clostridium difficile infection. Dr David R Jenkins University Hospitals of Leicester NHS Trust, England

The Infection Control Doctor and Clostridium difficile infection. Dr David R Jenkins University Hospitals of Leicester NHS Trust, England The Infection Control Doctor and Clostridium difficile infection Dr David R Jenkins University Hospitals of Leicester NHS Trust, England 250 200 150 100 50 0 Monthly cases of Clostridium difficile (UHL

More information

Volume 2; Number 14 September 2008 NICE CLINICAL GUIDELINE 66: TYPE 2 DIABETES THE MANAGEMENT OF TYPE 2 DIABETES (MAY 2008)

Volume 2; Number 14 September 2008 NICE CLINICAL GUIDELINE 66: TYPE 2 DIABETES THE MANAGEMENT OF TYPE 2 DIABETES (MAY 2008) Volume 2; Number 14 September 2008 NICE CLINICAL GUIDELINE 66: TYPE 2 DIABETES THE MANAGEMENT OF TYPE 2 DIABETES (MAY 2008) The purpose of this special edition of the PACE Bulletin is to summarize the

More information

Date: October 3, 2017 To: Participating Providers From: YourCare Health Plan Provider Relations Subject: 2018 Formulary Changes

Date: October 3, 2017 To: Participating Providers From: YourCare Health Plan Provider Relations Subject: 2018 Formulary Changes Date: October 3, 2017 To: Participating Providers From: YourCare Health Plan Provider Relations Subject: 2018 Formulary Changes 2018 Formulary-UM Changes What does this mean now, and for 2018? A number

More information

Understanding Your Patient Care Opportunity Report (PCOR)

Understanding Your Patient Care Opportunity Report (PCOR) Understanding Your Patient Care Opportunity Report (PCOR) Use your January/February 208 PCOR to help improve performance on Medicare Part D Clinical Star Ratings measures. Your January/February 208 Patient

More information

How many spoonfuls of sugar? A Bert s-eye view of prescribing to manage blood sugar

How many spoonfuls of sugar? A Bert s-eye view of prescribing to manage blood sugar How many spoonfuls of sugar? A Bert s-eye view of prescribing to manage blood sugar What would Mary Poppins think? Please discuss Some Sums Annual cost of diabetes (1 &2) in England = c. 24 billion Around

More information

Common Mental Health Disorders

Common Mental Health Disorders Hastings and Rother Clinical Commissioning Group This profile has been developed to support the Mental Health Intelligence Network s aim to improve the health of communities by making data and information

More information

Prescribing Indicators Examples from Germany

Prescribing Indicators Examples from Germany Prescribing Indicators Examples from Germany The Managed Introduction of New Medicines Second Piperska Workshop 19-21 March 2012, Ljubljana Gisbert W. Selke 2012-02-08 Agenda The QISA indicator set Case

More information

DT Description Price Category Price change

DT Description Price Category Price change Tariff T Watch October 2014 Readers are no doubt aware of this quarter's bad news for primary care prescribing allocations: NHS England has d the remuneration mechanism for community pharmacies gaining

More information

High Risk Medicines Prescribing Policy. July 2017

High Risk Medicines Prescribing Policy. July 2017 High Risk Medicines Prescribing Policy July 2017 Responsible Committee: Quality Committee Date Effective: July 2017 Author: Rahinatu Amadu Supersedes: July 2016 Next Review Due: July 2018 1. INTRODUCTION

More information

The PROMPT criteria: Development and validation of prescribing indicators in middle-aged adults

The PROMPT criteria: Development and validation of prescribing indicators in middle-aged adults The PROMPT criteria: Development and validation of prescribing indicators in middle-aged adults Dr. Janine Cooper, Professor Carmel Hughes, Dr. Cristín Ryan, Professor Susan Smith, Dr. Emma Wallace, Dr.

More information

DT Description Price Category Price change Percentage BNF 1.2 Mebeverine 135mg tablets (100) 759 M %

DT Description Price Category Price change Percentage BNF 1.2 Mebeverine 135mg tablets (100) 759 M % June 2016 On 13th May, the DH announced that there would be reductions to Category M prices from June until September. http://psnc.org.uk/our-news/contractor-notice-category-m-price-reduction/ This has

More information

Proton Pump Inhibitors. Description. Section: Prescription Drugs Effective Date: July 1, 2014

Proton Pump Inhibitors. Description. Section: Prescription Drugs Effective Date: July 1, 2014 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.09.01 Subject: Proton Pump Inhibitors Page: 1 of 7 Last Review Date: June 12, 2014 Proton Pump Inhibitors

More information

ANNOUNCEMENT. Dear Valued Customer:

ANNOUNCEMENT. Dear Valued Customer: ANNOUNCEMENT Dear Valued Customer: This is to notify you that Ranbaxy Canada s products will not be currently distributed to you through Kohl and Frisch; however Kohl and Frisch will continue their support

More information

Table 1: Guideline data collection

Table 1: Guideline data collection Table 1: Guideline data collection Guideline table Arguments Key Guideline number Numerical number to allocate the. Numerical number Filenames File name of the record. e.g. G0001.csv Guideline name Identity

More information

Approval of proposals for various pharmaceuticals

Approval of proposals for various pharmaceuticals 9 August 2010 Approval of proposals for various pharmaceuticals PHARMAC is pleased to announce the approval of proposals for pharmaceuticals in several therapeutic groups which aim to address some issues

More information

Measuring and Evaluating Indicators of Appropriate Prescribing in Older. Populations

Measuring and Evaluating Indicators of Appropriate Prescribing in Older. Populations HRB PhD Scholar Division of Population Health Sciences RCSI Measuring and Evaluating Indicators of Appropriate Prescribing in Older Cost-Effective Proton Pump Populations Potential Strategies for more

More information

Guidelines for the Management of Dyspepsia and GORD. Gastroenterology/ Acute Adult Governance. Drugs and Therapeutics Committee

Guidelines for the Management of Dyspepsia and GORD. Gastroenterology/ Acute Adult Governance. Drugs and Therapeutics Committee Guidelines for the Management of Dyspepsia and GORD Document type: Version: 3.0 Author (name): Author (designation): Validated by Prescribing Dr. G. Lipscomb Date validated October 2015 Ratified by: Date

More information

ARBS MEDICATION(S) SUBJECT TO STEP THERAPY DIOVAN HCT MG TAB, DIOVAN HCT MG TABLET

ARBS MEDICATION(S) SUBJECT TO STEP THERAPY DIOVAN HCT MG TAB, DIOVAN HCT MG TABLET ARBS DIOVAN HCT 160-12.5 MG TAB, DIOVAN HCT 80-12.5 MG TABLET 30-day trial of a Step 1 drug in the previous 120 days is required. Step 1 Drugs: Losartan, Losartan/HCTZ PAGE 1 LAST UPDATED 05/2016 BILE

More information

Proton Pump Inhibitors

Proton Pump Inhibitors Market DC Proton Pump Inhibitors Override(s) Prior Authorization Quantity Limit** Approval Duration Preferred PPI: No Prior Authorization required Preferred PPI quantity override: Lifetime Non-Preferred

More information

ATYPICAL ANTIPSYCHOTICS

ATYPICAL ANTIPSYCHOTICS Step Therapy CareOregon 2018 Last Updated: 07/27/2018 ATYPICAL ANTIPSYCHOTICS Fanapt Fanapt Titration Pack Paliperidone Er Vraylar The following criteria applies to members who newly start on the drug:

More information

Identifying patients who may benefit from stepping down PPI treatment

Identifying patients who may benefit from stepping down PPI treatment CLINICAL AUDIT Identifying patients who may benefit from stepping down PPI treatment Valid to January 2024 bpac nz better medicin e This audit identifies patients who are prescribed the proton pump inhibitor

More information

Antibiotic Consumption in the Community in Ireland REPORT FOR First Half of 2013

Antibiotic Consumption in the Community in Ireland REPORT FOR First Half of 2013 Antibiotic Consumption in the Community in Ireland REPORT FOR First Half of 2013 1 Summary: Community Antibiotic Use The rate for Quarter 1 of 2013 (1 st January to 31 st March) was 27.4 Defined Daily

More information

Forecasting and Monitoring Budgetary impact and medicines uptake

Forecasting and Monitoring Budgetary impact and medicines uptake Forecasting and Monitoring Budgetary impact and medicines uptake Kate Jenkins and Paul Deslandes Welsh Analytical Prescribing Support Unit All Wales Therapeutics and Toxicology Centre WAPSU Remit Medicines

More information

5-ASA. Products Affected Dipentum 250 mg capsule. Details. Lialda 1.2 gram tablet,delayed release

5-ASA. Products Affected Dipentum 250 mg capsule. Details. Lialda 1.2 gram tablet,delayed release 5-ASA Dipentum 250 mg capsule Lialda 1.2 gram tablet,delayed release You are required to have previous therapy with balsalazide, Delzicol, Apriso, or Asacol HD before we will cover Lialda or Dipentum.

More information

We would like to take the opportunity to acknowledge the following individuals and groups:

We would like to take the opportunity to acknowledge the following individuals and groups: ACKNOWLEDGEMENTS We would like to take the opportunity to acknowledge the following individuals and groups: Dr Simon Hurding and Sean MacBride-Stewart who have been instrumental in the development of this

More information

Prevpac Pylera Omeclamox-Pak

Prevpac Pylera Omeclamox-Pak Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.21 Subject: -Pak Page: 1 of 5 Last Review Date: September 20, 2018 -Pak Description (lansoprazole,

More information

Prakruti Life Science

Prakruti Life Science Prakruti Life Science is a well established and recognized name in pharmaceutical industry in India. Prakruti Life Science Pvt Ltd is located at coastal belt of Karnataka. The Manufacturing Unit is situation

More information

ASEBP and ARTA TARP Drugs and Reference Price by Categories

ASEBP and ARTA TARP Drugs and Reference Price by Categories ASEBP Pantoprazole Sodium 40 mg (generic) $0.2016 ASEBP Dexlansoprazole 30 mg Dexlansoprazole 60 mg Esomeprazole 10 mg Esomeprazole 20 mg Esomeprazole 40 mg Lansoprazole 15 mg Lansoprazole 30 mg Omeprazole

More information

National Therapeutic Indicators and Additional Prescribing Measures 2017/18 - Early Release Document

National Therapeutic Indicators and Additional Prescribing Measures 2017/18 - Early Release Document National Therapeutic Indicators and Additional Prescribing Measures 2017/18 - Early Release Document 1 National Therapeutic Indicators 2017-18 National Therapeutic Indicators (NTIs) and Additional Prescribing

More information

GASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali

GASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS by: Shaema M. Ali There are four common medical conditions involving the GI system 1) peptic ulcers

More information

Wolverhampton CCG Medicines Optimisation Work plan 2017/18

Wolverhampton CCG Medicines Optimisation Work plan 2017/18 Wolverhampton CCG Medicines Optimisation Work plan 2017/18 Wolverhampton Clinical Commissioning Group 1 Contents page Overall Outcomes 3 Patient Safety 3 Medicines Commissioning 4 QIPP 5 Areas of cost

More information

National Prescribing Indicators Supporting Information for Prescribers

National Prescribing Indicators Supporting Information for Prescribers National Prescribing Indicators 2018 2019 Supporting Information for Prescribers February 2018 This report has been prepared by a multiprofessional collaborative group, with support from the All Wales

More information

COMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées

COMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées OPTIMAL THERAPY REPORT COMPUS Volume 1, Issue 6 March 2007 Gap Analysis Report for the Prescribing and Use of Proton Pump Inhibitors (PPIs) Supporting Informed Decisions À l appui des décisions éclairées

More information

2017 AlohaCare Advantage Plus Formulary (HMO SNP) Drugs with Step Therapy Requirements

2017 AlohaCare Advantage Plus Formulary (HMO SNP) Drugs with Step Therapy Requirements 2017 AlohaCare Advantage Plus Formulary (HMO SNP) Drugs with Step Therapy Requirements AlohaCare requires you to first try one drug to treat your medical condition before we will cover another drug for

More information

The first stop for professional medicines advice. Community Pharmacy NSAID Gastro-Intestinal Safety Audit

The first stop for professional medicines advice. Community Pharmacy NSAID Gastro-Intestinal Safety Audit Community Pharmacy NSAID Gastro-Intestinal Safety Audit Working with Primary Care Commissioning, Strategy and Innovation Directorate The first stop for professional medicines advice www.sps.nhs.uk Community

More information

Medicinal products of Kusum Pharm Ltd. registered in Ukraine - 1 -

Medicinal products of Kusum Pharm Ltd. registered in Ukraine - 1 - - 1-1. Abrol tablets 30, No. 20 (10 2) in 1 tablet contains ambroxol hydrochloride 30 UA/9928/01/01 2. Abrol syrup, 15 /5 ml, 100 ml in a bottle 5 ml of syrup contain ambroxol hydrochloride15 Medicines

More information

General practice. Prescribing indicators for UK general practice: Delphi consultation study. Abstract. Introduction. Participants and methods

General practice. Prescribing indicators for UK general practice: Delphi consultation study. Abstract. Introduction. Participants and methods National Primary Care Research and Development Centre, University of Manchester, Manchester M13 9PL Stephen M Campbell research fellow Judy A Cantrill clinical senior lecturer Prescribing Support Unit,

More information

2018 Step Therapy Criteria

2018 Step Therapy Criteria 2018 Step Therapy Criteria ANGIOTENSIN RECEPTOR BLOCKERS... 2 ANTIDEPRESSANTS... 3 ANTIDEPRESSANTS, MISCELLANEOUS... 4 ANTIDEPRESSANTS, OTHER... 5 ANTIDIABETIC AGENTS... 6 ANTIGOUT AGENTS... 7 ANTIHYPERTENSIVE

More information

5-ASA. Products Affected Dipentum 250 mg capsule. Details. Lialda 1.2 gram tablet,delayed release

5-ASA. Products Affected Dipentum 250 mg capsule. Details. Lialda 1.2 gram tablet,delayed release 5-ASA Dipentum 250 mg capsule Lialda 1.2 gram tablet,delayed release You are required to have previous therapy with balsalazide, Delzicol, Apriso, or Asacol HD before we will cover Lialda or Dipentum.

More information

Texas Vendor Drug Program. Formulary Drug Index File Layout. Layout effective: Jul. 2, 2018 Document update: Oct. 1, 2018

Texas Vendor Drug Program. Formulary Drug Index File Layout. Layout effective: Jul. 2, 2018 Document update: Oct. 1, 2018 Texas Vendor Drug Program Formulary Drug Index File Layout Layout effective: Jul. 2, 2018 Document update: Oct. 1, 2018 The Vendor Drug Program provides a weekly update of resource data available for download

More information

National Medicines Management Programme

National Medicines Management Programme National Medicines Management Programme Michael Barry 28 th November 2013 The Medicines Management Programme Multi-disciplinary Medicines Management Programme (MMP) headed by the National Medicines Information

More information

International IBD Genetics Consortium

International IBD Genetics Consortium International IBD Genetics Consortium PRED4 Proton Pump Inhibitor Induced Nephritis Case Report FormS Please stick study label here On completion, please return to: IBD Pharmacogenetics Research Office

More information

American Diabetes Association 2018 Guidelines Important Notable Points

American Diabetes Association 2018 Guidelines Important Notable Points American Diabetes Association 2018 Guidelines Important Notable Points The Standards of Medical Care in Diabetes-2018 by ADA include the most current evidencebased recommendations for diagnosing and treating

More information

SW Locality PBC Consortium Notes re Prescribing Data

SW Locality PBC Consortium Notes re Prescribing Data SW Locality PBC Consortium Notes re Prescribing Data Enclosed data is for SW Locality PBC Consortium practices from current 12 months as at Mar 07 Top 50 by cost identified Areas that could achieve quick

More information

UF Decision Report FY06-07 Beneficiary Advisory Panel 10 Jan 2008

UF Decision Report FY06-07 Beneficiary Advisory Panel 10 Jan 2008 UF Decision Report FY06-07 Beneficiary Advisory Panel 10 Jan 2008 Promoting high quality, cost effective drug therapy throughout the Military Health System UF Decisions, May 07 Class FY05 rank, total $

More information

Mediscor Medicines Review 2011

Mediscor Medicines Review 2011 Mediscor Medicines Review 2011 Mediscor Client Workshop 2012 28 August 2012 Presented by: Madelein Bester Benefit Management Mediscor PBM Content Background of the report Overall trends Expenditure per

More information

A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS. Pan-Canadian Select Molecule Price Initiative for Generic Drugs

A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS. Pan-Canadian Select Molecule Price Initiative for Generic Drugs Pharmacy Benefact A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS Number 723 February 2018 Pan-Canadian Select Molecule Price Initiative for Generic Drugs Alberta Drug Benefit List prices

More information

Short-acting insulins. Biphasic insulins. Intermediate- and long-acting insulins

Short-acting insulins. Biphasic insulins. Intermediate- and long-acting insulins Recommended Insulin Products This guideline states the Gloucestershire Joint Formulary recommended, first choice insulin products. The intention is to support the choice of treatment for new patients,

More information

BNF. BACKGROUND FOR USE

BNF. BACKGROUND FOR USE 797FM.2 ORAL ANTICOAGULANTS WARFARIN, ACENOCOUMAROL AND PHENINDIONE, WHEN DOSES ARE ADJUSTED BY THE ANTICOAGULATION CLINIC AND PRESCRIBED BY THE GENERAL PRACTITIONER (GP) Shared Care Protocol This protocol

More information

NSAIDs Change Package 2017/2018

NSAIDs Change Package 2017/2018 NSAIDs Change Package 2017/2018 Aim: To Reduce harm to patients from Non-Steroidal Anti-inflammatory Drugs (NSAIDs) in primary care Background A key aim of the Safety in Practice programme is to reduce

More information

COMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées

COMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées OPTIMAL THERAPY REPORT COMPUS Volume 1, Issue 5 March 2007 Current Practice Analysis Report for the Prescribing and Use of Proton Pump Inhibitors (PPIs) Supporting Informed Decisions À l appui des décisions

More information

Step Therapy Criteria (Criteria for Step Therapy-2 [ST-2] Drugs)

Step Therapy Criteria (Criteria for Step Therapy-2 [ST-2] Drugs) CareAdvantage CMC 2018 Formulary Supplement II (List of Covered Drugs) Step Therapy Criteria (Criteria for Step Therapy-2 [ST-2] Drugs) Formulary ID: 00018157 Formulary Version:11 19 CMS Approved: 08/21/2018

More information

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures

More information

Fionnuala Plumart, Jade Tomes, Nick Rutherford Medicines Management Team, Brighton and Hove CCG

Fionnuala Plumart, Jade Tomes, Nick Rutherford Medicines Management Team, Brighton and Hove CCG Fionnuala Plumart, Jade Tomes, Nick Rutherford Medicines Management Team, Brighton and Hove CCG Why have we created this role? Processing 100 + repeat requests a day Constant phone ringing Many different

More information

Glossary of Medications

Glossary of Medications CLPNA Medications Administration Module Glossary of Medications Acetaminophen. Acetaminophen is a non-opioid analgesic used to manage mild pain and fever. Acetylsalicylic acid. Acetylsalicylic acid is

More information

Drug Class Review on Proton Pump Inhibitors

Drug Class Review on Proton Pump Inhibitors Drug Class Review on Proton Pump Inhibitors Final Report Update 4 July 2006 Original Report Date: November 2002 Update 1 Report Date: April 2003 Update 2 Report Date: April 2004 Update 3 Report Date: May

More information

Condition/Procedure Measure Compliance Criteria Reference Attribution Method

Condition/Procedure Measure Compliance Criteria Reference Attribution Method Premium Specialty: Cardiology Credentialed Specialties include: Cardiac Diagnostic, Cardiology, Cardiovascular Disease, Clinical Cardiac Electrophysiology, and Interventional Cardiology This document is

More information

Guidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010

Guidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010 Guidelines to assist General Practitioners in the Management of Type 2 Diabetes April 2010 Foreword The guidelines were devised by the Diabetes Day Centre in Beaumont Hospital in consultation with a number

More information

Clinical Guidelines. Management of adult patients with diabetes undergoing endoscopic procedures

Clinical Guidelines. Management of adult patients with diabetes undergoing endoscopic procedures Clinical Guidelines Management of adult patients with diabetes undergoing endoscopic s Document Detail Document type Clinical Guideline Management of adult Patients with diabetes Undergoing Document name

More information

PHARMA-MEDIC SERVICES INC. POLICY MANUAL

PHARMA-MEDIC SERVICES INC. POLICY MANUAL PHARMA-MEDIC SERVICES INC. POLICY MANUAL SUBJECT: INDEX: P.5.a.iii Automatic-Therapeutic Substitution DATE: June 1/2011 REVISED: March 2, 2015., Feb 2017. PROCEDURE: 1. Long term care homes use the Manitoba

More information

MAXIMUM ALLOWABLE COST POLICY CHANGES DECEMBER 5, 2016 QUESTIONS AND ANSWERS

MAXIMUM ALLOWABLE COST POLICY CHANGES DECEMBER 5, 2016 QUESTIONS AND ANSWERS MAXIMUM ALLOWABLE COST POLICY CHANGES DECEMBER 5, 2016 QUESTIONS AND ANSWERS The November 22, 2016 Mid-Year Financial Report referred to changes to drug coverage under the Saskatchewan Drug Plan. What

More information

ALLERGIC RHINITIS-NASAL

ALLERGIC RHINITIS-NASAL ALLERGIC RHINITIS-NASAL FLUNISOLIDE Patient needs to have paid claims for any one of the following Step 1 drugs: NasaCort OTC, fluticasone Rx, fluticasone OTC, Budesonide OTC. Prior to filling the Step

More information

A C A D E M I C D E TA I L I N G C H O O S I N G W I S E LY C O N F E R E N C E O C T 2 1, PA M M C L E A N - V E Y S E Y B S C P H A R M D R

A C A D E M I C D E TA I L I N G C H O O S I N G W I S E LY C O N F E R E N C E O C T 2 1, PA M M C L E A N - V E Y S E Y B S C P H A R M D R PPI DEPRESCRIBING Canadian Deprescribing Network (CaDeN) goals are to: Reduce harm by raising awareness and cutting risky prescriptions for seniors by 50% by 2020. Promote health by ensuring access to

More information

Community Pharmacy Support Guidance: Electronic Repeat Dispensing (erd)

Community Pharmacy Support Guidance: Electronic Repeat Dispensing (erd) Community Pharmacy Support Guidance: Electronic Repeat Dispensing (erd) Version: 2.1 Date Published October 2018 Author: Rachel Raybould, Midland and Lancashire CSU 1 Introduction: Welcome to the Community

More information

Proton Pump Inhibitors (PPIs) (Sherwood Employer Group)

Proton Pump Inhibitors (PPIs) (Sherwood Employer Group) Proton Pump Inhibitors (PPIs) (Sherwood Employer Group) BCBSKS will review Prior Authorization requests Prior Authorization Form: https://www.bcbsks.com/customerservice/forms/pdf/priorauth-6058ks-st-ippi.pdf

More information

While there is around a 3% increase shown in costs for Category M lines, I think this is due to the inclusion of more lines in Category M.

While there is around a 3% increase shown in costs for Category M lines, I think this is due to the inclusion of more lines in Category M. April 2018 The usual quarterly of Category M prices Another set of similar comments as I made in January: significant increases in many lines which have been subject to price concessions but even more

More information

Vimovo (delayed-release enteric-coated naproxen with esomeprazole)

Vimovo (delayed-release enteric-coated naproxen with esomeprazole) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.17.01 Subject: Vimovo Page: 1 of 5 Last Review Date: September 18, 2015 Vimovo Description Vimovo (delayed-release

More information

Patient advice regarding long term use of Proton Pump Inhibitors (PPIs)

Patient advice regarding long term use of Proton Pump Inhibitors (PPIs) Patient advice regarding long term use of Proton Pump Inhibitors (PPIs) Information for you Follow us on Twitter @NHSaaa Find us on Facebook at www.facebook.com/nhsaaa Visit our website: www.nhsaaa.net

More information

Medicines save lives

Medicines save lives Optimizing Aging Collaborative Disclosures Too much of a good thing: No financial interests to disclose John Newman, MD, PhD Assistant Professor Division of Geriatrics, UCSF Kirby Lee, PharmD, MAS Associate

More information

There have been important changes in diabetes care which may not be covered in undergraduate textbooks.

There have been important changes in diabetes care which may not be covered in undergraduate textbooks. Diabetes Clinical update There have been important changes in diabetes care which may not be covered in undergraduate textbooks. Changes in the diagnosis of diabetes a) HbA1C Since 2011, World Health Organisation

More information